QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.103481v1 318/3/939    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petrangolini, G. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by Petrangolini, G. Articles by Zunino, F.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Effect of a Novel Vacuolar-H⁺-ATPase Inhibitor on Cell and Tumor Response to Camptothecins

Istituto Nazionale Tumori, Milan, Italy (G.Pe., R.S., G.Pr., L.D.B., M.T., F.Z.); Consiglio Nazionale delle Ricerche, Università di Pavia, Pavia, Italy (A.C.C.); and Nikem Research, Baranzate, Milan, Italy (P.M., P.B., C.F.)

The vacuolar-H⁺-ATPase, functionally expressed in cell membranes, is known to play a relevant role in intracellular pH regulatory mechanisms, because it is implicated in pumping protons into the extracellular environment or in sequestrating excess protons into acidic vacuolar compartments. Because tumor cells exist in a hypoxic microenvironment and produce acidic metabolites, this regulatory mechanism is recognized as a protective function. This study was designed to investigate the effect of NiK-12192 [4-(5,6-dichloro-1H-indol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-benzamide], an indole derivative identified as an effective inhibitor of vacuolar-H⁺-ATPase, on the cytotoxic activity of two camptothecins, i.e., topotecan and SN-38 (7-ethyl-10-hydroxycamptothecin, the active metabolite of irinotecan). The cellular studies performed in two pairs of human colon carcinoma cell lines, i.e., LoVo and LoVo/DX (overexpressing P-glycoprotein) and HT29 and HT29/Mit (overexpressing breast cancer resistant protein), indicated an enhancement of the antiproliferative effect of camptothecins by concomitant exposure to subtoxic concentrations of NiK-12192. Studies of subcellular distribution indicated that whereas topotecan alone localized mainly in mitochondria and endoplasmic compartment, the simultaneous presence of NiK-12192 caused a cytoplasmic redistribution. In HT29/Mit cells, NiK-12192 reverted the pattern of acidification induced by topotecan. The potentiation of topotecan efficacy by NiK-12192 was documented by an increased efficacy of the combination in both the HT29 tumor xenografts, being more evident in the topotecan-resistant HT29/Mit tumor. In conclusion, the vacuolar-H⁺-ATPase inhibitor NiK-12192 was able to potentiate the cytotoxic/antitumor effects of camptothecins, either in in vitro or in in vivo systems. Such findings support a potential interest for the use of vacuolar-H⁺-ATPase inhibitors in combination therapy to improve camptothecin efficacy.

Address correspondence to: Dr. Franco Zunino, Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy. E-mail: franco.zunino{at}istitutotumori.mi.it

This article has been cited by other articles:

				R. Supino, G. Petrangolini, G. Pratesi, M. Tortoreto, E. Favini, L. D. Bo, P. Casalini, E. Radaelli, A. C. Croce, G. Bottiroli, et al. Antimetastatic Effect of a Small-Molecule Vacuolar H+-ATPase Inhibitor in in Vitro and in Vivo Preclinical Studies J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 15 - 22. [Abstract] [Full Text] [PDF]

				P. Provent, M. Benito, B. Hiba, R. Farion, P. Lopez-Larrubia, P. Ballesteros, C. Remy, C. Segebarth, S. Cerdan, J. A. Coles, et al. Serial In vivo Spectroscopic Nuclear Magnetic Resonance Imaging of Lactate and Extracellular pH in Rat Gliomas Shows Redistribution of Protons Away from Sites of Glycolysis Cancer Res., August 15, 2007; 67(16): 7638 - 7645. [Abstract] [Full Text] [PDF]

				K. H. Weylandt, M. Nebrig, N. Jansen-Rosseck, J. S. Amey, D. Carmena, B. Wiedenmann, C. F. Higgins, and A. Sardini ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment Mol. Cancer Ther., March 1, 2007; 6(3): 979 - 986. [Abstract] [Full Text] [PDF]